Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia

Novel drugs are needed to increase treatment response in children with high-risk T-cell acute lymphoblastic leukemia (T-ALL). Following up on our previous report on the activation of the MAP2K7-JNK pathway in pediatric T-ALL, here we demonstrate that OTSSP167, recently shown to inhibit MAP2K7, has a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bridges, Cory Seth, Chen, Taylor J., Puppi, Monica, Rabin, Karen R., Lacorazza, H. Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979715/
https://www.ncbi.nlm.nih.gov/pubmed/36399528
http://dx.doi.org/10.1182/bloodadvances.2022008548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979715/
https://www.ncbi.nlm.nih.gov/pubmed/36399528
http://dx.doi.org/10.1182/bloodadvances.2022008548

Ejemplares similares